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Urinary symptoms of benign prostatic hyperplasia (BPH) may affect sexual function, 
considered by patients themselves to be one of the most important aspects of the 
disease. Though lack of consensus on the underlying mechanism involved, some 
hypothesis are accounted for this association, such as autonomic hyperactivity, de-
creased nitric oxide (NO) production in the prostate and penile cavernous muscle, 
as well as pelvic atherosclerosis and endothelial dysfunction.
 Although medical treatment with α-blockers and/or 5α-reductase inhibitors are 
the mainstays of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/
LUTS), there are some contradictory bias on the effect of sexual function either 
erectile or ejaculatory function.
 α-blocker is currently recommended as a first line treatment of BPH. Since it will 
reduce the sympathetic overstimulation of prostate, it may also affect the similar 
pathway in penis. It has been suggested that α-blockers may improve sexual func-
tion in patients with BPH. However, among α-blockers, tamsulosin is associated 
with an increased risk of ejaculation disorders. Long-term use of 5α-reductase in-
hibitors alone or combined with α-blockers will cause reduction of prostate volume 
and improved the clinical symptoms; however, it may associate with sexual prob-
lems, especially ejaculation disorders.
 Based on the already published data, the effect of α-blockers and 5α-reductase 
inhibitors on the sexual function will be reviewed. Moreover, this may reinforce physi-
cians to manage appropriately these two highly prevalent and bothersome conditions.
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1. Introduction
Pharmacological treatment has become the primary 
choice for symptomatic benign prostate hyperplasia 
(BPH), and it has been shown to be effective in improving 
short-term outcomes (maximal flow rate and symptom 
scores). The two principal drugs prescribed for BPH are 
α-blockers and 5α-reductase inhibitors.1,2 Urologists are 
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familiar with the nonsexual side effects of α-adrenergic 
blockers, as these effects are well documented.2,3 However, 
some treatments for BPH may affect sexual function.4–8 
The sexual side effects, particularly ejaculatory dysfunction, 
are not as well studied, and there is even less information 
on the beneficial effects of these medications, particularly 
any positive effects on erectile function and sexual satis-
faction. Medical treatment of BPH with finasteride may be 
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associated with erectile dysfunction (ED) (6.6–9.0%).4,5,7 
However, α-blockade is not associated with this side effect. 
The beneficial effects of treatments for BPH need to be 
reported equally against the morbidities associated with 
these treatments.
Some researchers believe that lower urinary tract 
symptoms (LUTSs)/BPH should be considered an inde-
pendent risk factor for sexual dysfunction.5,7 They con-
cluded that older men can still have an active sexual 
life.9,10 The severity of LUTSs has a direct impact on sex-
ual disorders; therefore, sexual function should be con-
sidered when choosing BPH treatments. Most Asian 
men in the age group of 50–80 years are sexually active, 
and over half of them are affected by sexual dysfunc-
tion.5 However, a small study that enrolled 50 men with 
symptomatic BPH in Taiwan showed no obvious corre-
lation between the International Prostate Symptom 
Score and International Index of Erectile Function-15 
scores.6
2. Adverse Effects on Sexual Function
2.1. Five alpha-reductase inhibitors
Some clinical trials (VA, PROWESS, and PLESS) showed 
that 5α-reductase inhibitors such as finasteride can 
have adverse impacts on libido, potency, and ejaculatory 
function, which suggest a negative impact on the quality 
of life.7,11–13 The probabilities of the occurrence of nega-
tive effects on sexual function with finasteride are 
2–10% for decreased libido, 3–16% for ED (Table 1), and 
0–8% for ejaculatory disorders.7,14 The PROSPECT trial, 
involving 472 men who completed 2 years of therapy 
with finasteride, showed a 15.8% incidence of ED in the 
treatment arm vs. 6.3% in the placebo arm (p = 0.01).15 
Finasteride has also been shown to impair libido. In ran-
domized clinical trials, the incidence of impaired libido 
with finasteride ranges from 3.1–5.4%.16 Dutasteride, an 
inhibitor of both type 1 and 2 5α-reductase isozymes, 
has been investigated for treating BPH since 1997.17 The 
dual inhibitory effect of dutasteride produces nearly 
complete suppression of serum dihydrotestosterone in 
healthy male subjects. Abnormal ejaculation has been 
reported in a considerable number of patients (Figure 1) 
including a reduced ability to ejaculate, dry ejaculation, 
and painful ejaculation.18 However, < 1% of patients discon-
tinue the treatment because of such adverse events.15,16 
Ejaculatory dysfunction, like other sexual dysfunctions 
associated with finasteride, tends to occur earlier in the 
therapeutic duration. Most subjects experience symptoms 
within the first 9 months of treatment.16
2.2. Alpha 1-blockers
Blockade of α-receptors in the bladder neck causes 
muscle relaxation, which allows semen to flow back into 
the bladder during climax (retrograde ejaculation). The 
risk from α-blockade is generally < 1%, although it can 
be higher with certain agents such as tamsulosin. The 
pharmacological specificity of α-blockers varies accord-
ing to the subtypes of α1-adrenergic receptors. The α1A 
subtype appears to predominate in the bladder neck, 
prostatic smooth muscle, seminal vesicles, and vas defer-
ens, and is involved in producing contractions.19 Terazosin 
appears to be associated with a relatively lower incidence 
of ejaculatory dysfunction. The incidence of ejaculatory 
dysfunction with terazosin is 0.3%.11 With alfuzosin, one 
study found no incidence of abnormal ejaculation.20 
Ejaculatory dysfunction with doxazosin has not been ade-
quately studied.21
In contrast, tamsulosin is associated with a signifi-
cant incidence of ejaculatory dysfunction, which may be 
caused by its higher pharmacological selectivity for α1A-
receptors in the bladder neck, seminal vesicles, and vas 
deferens. In Chapple et al’s trial, the incidence of ejacu-
latory dysfunction was 4.5% with tamsulosin vs. 1.0% 
with a placebo (p = 0.045).22 Lepor et al. reported a 6.0% 
incidence of abnormal ejaculation in tamsulosin-treated 
patients, which was significantly higher than that with 
a placebo (p < 0.001).23
Abnormal ejaculation is easily identified by a low 
ejaculate volume on semen analysis and a finding of 
sperm in the postejaculate urine. In all of the trials cited 
Table 1 Impact of 5α-reductase inhibitors on sexual function
 VA study, PROWESS study, PLESS study,
 1-year follow-up 2-year follow-up  1-year follow-up
 Placebo Drug Placebo Drug Placebo Drug
Side effects
 (n = 305) (n = 310) (n = 1591) (n = 1577) (n = 1376) (n = 1384)
Decreased libido (%) 1.0 5.0 2.8 4.0 3.4 6.4
Erectile dysfunction (%) 5.0 9.0 4.7 6.6 3.7 8.1
Decreased ejaculation (%) NA NA NA NA 0.8 3.7
Ejaculation disorders (%) 1.0 2.0 0.6 2.1 0.1 0.8
NA = not available. VA = Veterans Affairs Cooperative Studies; PROWESS = PROscar Worldwide Efficacy and Safety Study; PLESS = PROscar 
Long-term Efficacy and Safety Study Group; PROSPECT = PROscar Safety Plus Efficacy Canadian Two-year Study.
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above, cessation of the medication resulted in resolu-
tion of symptoms of ejaculatory dysfunction.
3. Beneficial Effects on Sexual Function
Several studies have shown a beneficial effect of α1-
antagonists on overall sexual function. Kirby et al. reported 
that both doxazosin XL (eXtended reLease) and the 
standard dose improved sexual function in men with 
concomitant BPH and ED.8 Kaplan et al. reported that addi-
tional doxazosin improved International Index of Erectile 
Function scores in patients for whom intracavernosal ther-
apy had failed.24 De Rose et al. attempted to use sildena-
fil combined with doxazosin for ED patients unresponsive 
to 3 months of sildenafil monotherapy.25 They found that 
11 of 14 patients (78.6%) showed a statistically significant 
increase in their International Index of Erectile Function 
scores. In addition, alfuzosin (10 mg) once daily has also been 
reported to improve sexual function in men with LUTSs and 
sexual dysfunction.26 That study suggested that in patients 
with sexual dysfunction, alfuzosin may improve both erec-
tile and ejaculatory dysfunction. Those improvements 
appeared to be strongly related to LUTSs and bothersome 
severity at baseline. Better improvement of erectile and 
ejaculatory function was observed in those patients who 
were severely affected (such as higher IPSS score and 
bothersome severity). The mechanism of how α1-blockers 
benefit sexual function remains to be elucidated. One 
possible explanation is that the improvement in LUTSs di-
rectly results in improvement in a patient’s quality of life by 
reducing psychological stress and restoring self-image.26
Recent experiments have shown that alfuzosin in-
duces relaxation of the isolated rabbit corpus caverno-
sum, and this is exclusively mediated through blockade 
of smooth muscle α-adrenoreceptors.27 It is well known 
that the sympathetic pathway plays a major role in penile 
detumescence and flaccidity through stimulation of post-
junctional α1-receptors of corpus cavernosum smooth 
muscle cells. Recently, it was reported that the cavernosal 
noradrenaline level is significantly decreased in healthy 
men during erection but not in patients with ED due to 
different causes. Furthermore, it was postulated that the 
contractile response of corpus cavernosum smooth mus-
cle cells mediated by adrenergic receptors increases with 
age.28 Since increased sympathetic tone appears to be 
common in patients with BPH, this may explain the high 
prevalence of ED in such aging patients. However, recent 
experiments showed that alfuzosin induces relaxation of 
isolated rabbit corpus cavernosum, and this was exclu-
sively mediated through blockade of smooth muscle α1 
adrenoreceptors.29
4.  Combined Therapy With a1-blockers and 
5a-reductase Inhibitors
Combined therapy with 5α-reductase inhibitors and α1-
blockers is more effective than monotherapy alone for 
improving symptoms, and long-term outcomes are im-
pressive in men with moderate to severe LUTSs and pro-
static enlargement (≥ 30 mL).30 Moreover, combination 
therapy significantly decreases the 4-year incidence of 
a composite endpoint of progression compared with 
doxazosin, finasteride, or a placebo, although at 1 year, 
combination therapy is superior to finasteride mono-
therapy but not to doxazosin monotherapy.29
Drug-related adverse events are numerically more 
common in combined therapy than with monotherapy, 
and these include ED (7.4%), retrograde ejaculation 
0
10
20
30
40
50
60
50
69
73
64
29
25
69
82
70
80
90
Reduced
ability to
ejaculate 
Delayed
ejaculaon
Dry
ejaculaon
Decreased
force of
ejaculaon
Decreased
amount of
semen
Painful
ejaculaon
*p < 0.001 
63
46
*
5α-reductase
inhibitor
Controls
Pe
rc
en
ta
ge
 o
f p
a
en
ts
26
*
46
Figure 1 Effect of 5α-reductase inhibitors on ejaculation dysfunction (MSHQ = Male Sexual Health Questionnaire).
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(4.2%), altered (decreased) libido (3.4%), ejaculation 
failure (2.4%), decreased semen volume (1.8%), loss of 
libido (1.7%), and nipple pain (1.2%).31,32 Overall, the pro-
file of events for combination therapy is consistent with 
that reported for the two monotherapies. Tamsulosin 
and dutasteride effect ejaculatory function, although 
probably via different mechanisms (such as adrenorecep-
tors and androgen receptors).33,34 This probably accounts 
for a greater than additive rate of ejaculatory dysfunction. 
Previous studies have shown that although the total 
number of drug-related adverse events was significantly 
greater in a combined group compared with that in either 
monotherapy group (α-blocker or 5α-reductase inhibitor), 
≤ 5% of the men in each treatment group, including the 
combined group, withdrew from the study as a result of 
those events. Therefore, those events did not lead to a sub-
stantial discontinuation rate in this population of elderly 
men.33,34
5. Conclusions
Different medical therapies have greater or lesser effects 
on sexual function in patients with BPH. Tamsulosin causes 
retrograde ejaculation, while 5α-reductase inhibitors 
affect the libido, and cause ED and low-volume ejacu-
late. Despite the statistical significance of the reported 
side effects, they are still relatively uncommon.
6. Further Perspectives
Sexuality in BPH patients needs to be further evaluated. 
Sexuality needs to be taken into consideration in the 
therapeutic strategy of BPH. Investigation of measure-
ments for evaluation of patients’ sexual function is re-
quired. In conclusion, sexual function and satisfaction 
with sex and one’s feelings need further investigation 
with respect to treatments for BPH.
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